Latest news from SABCS 2025
JANUARY 29, 2026
SABCS® 2025 Takeaways
Explore some of the notable discussions and potentially practice-changing data that were featured during the 48th annual San Antonio Breast Cancer Symposium®.
-
Special session explores key distinctions, considerations around breast cancer in young women
Panelists reviewed the biological features, treatment decisions, and ethical nuances around young-onset breast cancer.
-
Third General Session features supportive interventions for survivors, menopausal hormone therapy risk analysis, and more
Joanne Kotsopoulos, PhD; Ann H. Partridge, MD, MPH; and Jun J. Mao, MD, MSCE, were among the experts reporting findings Friday during the final General Session at the San Antonio Breast Cancer Symposium.
-
Plenary lecturer reviews work to enhance understanding of BRCA1/2-mediated tumorigenesis
Joan Brugge, PhD, shared new insights into breast tumorigenesis in BRCA1/2-mutation carriers.
-
AACR Distinguished Lectureship recipient shares goals for future applications of ctDNA detection
Ben Ho Park, MD, PhD, discussed the potential of circulating tumor DNA (ctDNA) to transform adjuvant treatment for breast cancer.
-
Second General Session reveals findings from de-escalation trials, preoperative radiotherapy study, and more
Gaorav Gupta, MD, PhD; Isabelle Bedrosian, MD; and Marjolein Smidt, MD, PhD, were among the experts reporting findings Thursday during the General Session at the San Antonio Breast Cancer Symposium.
-
Plenary panel outlines transformational role of patients and survivors as advocates, collaborators
Panelists discussed the vital role of patient advocacy in advancing breast cancer research, policy, and care.
